Clinical Trials Browser

Phase 1/2 × Neoplasms × cemiplimab × Clear all

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04706715 2025-05-31

LAG3 PET Imaging in Advanced Solid Tumors

Phase 1/2 Active not recruiting

41 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT06090266 2025-01-07

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Phase 1/2 Recruiting

168 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neoplasms

NCT05094804 2023-11-02

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Phase 1/2 Unknown

172 enrolled

DermatologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Leiomyosarcoma, Liposarcoma, Melanoma, Neoplasm Metastasis, Neoplasms

NCT03294083 2022-10-27

A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

Phase 1/2 Active not recruiting

89 enrolled

Genitourinary

Carcinoma, Renal Cell, Neoplasms

Clinical Trials

GLIMMER-01

LAG3 PET Imaging in Advanced Solid Tumors

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma